Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer

被引:57
|
作者
Gopal, R
Starkschall, G
Tucker, SL
Cox, JDC
Liao, ZX
Hanus, M
Kelly, JF
Stevens, CW
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 56卷 / 01期
关键词
radiotherapy; pulmonary toxicity; lung cancer; diffusion capacity;
D O I
10.1016/S0360-3016(03)00077-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effects of chemoradiation on objective tests of pulmonary function. Methods and Materials: One hundred lung cancer patients treated in five protocols between 1992 and 2000 with combinations of thoracic radiotherapy (RT) and chemotherapy were evaluated with pre- and post-RT pulmonary function tests. The pulmonary function tests were analyzed for changes in measures of obstruction (forced expiratory volume in 1 s per unit of vital capacity [FEV1/VC]), restriction (total lung capacity [TLC]), and diffusing capacity (diffusing capacity for carbon monoxide [DLCO]). The use and timing of chemotherapy and RT, as well as patient, tumor, and treatment factors, were evaluated using univariate and multivariate analyses. Results: No treatment or patient factors were significantly associated with changes in FEV1/VC. Chemotherapy with RT, compared with RT alone, was associated with a lower post-RT TLC (92% vs. 107%,p = 0.002). Nodal status (N2-N3 vs. N1)tumor location (central vs. peripheral), use of greater than or equal to6 treatment fields, and tumor volume greater than or equal to100 cm(3) were also associated with a significantly lower post-RT TLC. On univariate analysis, the use of any chemotherapy (p = 0.029) and the use of concurrent vs. sequential chemotherapy (p = 0.028) were predictive of a lower post-RT DLCO. Patient age greater than or equal to60 years, nodal status (N2-N3 vs. N0-N1), tumor volume greater than or equal to100 cm(3), tumor location (central vs. peripheral), and use of greater than or equal to6 treatment fields were also associated with a significantly lower post-RT DLCO. The fractional volume of irradiated normal lung correlated with the decrease in DLCO (p <0.001), with a 1.3% DLCO decline for each 1% of total lung volume that received >20 Gy. Conclusion: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation. (C) 2003 Elsevier Inc.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 50 条
  • [1] Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer
    Bernstein, ED
    Herbert, SM
    Hanna, NH
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (03) : 291 - 301
  • [2] Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer
    Seppenwoolde, Y
    De Jaeger, K
    Boersma, LJ
    Belderbos, JSA
    Lebesque, JV
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (03): : 748 - 758
  • [3] Current landscape of palliative radiotherapy for non-small-cell lung cancer
    Jumeau, Raphael
    Vilotte, Florent
    Durham, Andre-Dante
    Ozsahin, Esat-Mahmut
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S192 - S201
  • [4] Docetaxel (Taxotere®) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer
    Ornstein, DL
    Nervi, AM
    Rigas, JR
    ANNALS OF ONCOLOGY, 1999, 10 : 35 - 40
  • [6] The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer
    Tamburini, M
    Buccheri, G
    Brunelli, C
    Ferrigno, D
    SUPPORTIVE CARE IN CANCER, 2000, 8 (03) : 223 - 228
  • [7] The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer
    M. Tamburini
    G. Buccheri
    C. Brunelli
    D. Ferrigno
    Supportive Care in Cancer, 2000, 8 : 223 - 228
  • [8] Radiotherapy and targeted therapies in non-small-cell lung cancer
    Girard, N.
    Mornex, F.
    BULLETIN DU CANCER, 2009, 96 (03) : 311 - 319
  • [9] Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer
    Gray, Jhanelle
    Sommers, Eric
    Alvelo-Rivera, Miguel
    Robinson, Lary
    Bepler, Gerold
    ONCOLOGY-NEW YORK, 2009, 23 (10): : 879 - 886
  • [10] IS THERE A ROLE FOR CHEMOTHERAPY OF NON-SMALL-CELL LUNG-CANCER
    HANSEN, HH
    ANNALS OF ONCOLOGY, 1995, 6 : 79 - 82